Enliven Therapeutics, Inc. (ELVN) Cash Flow Statement

The persistent gap between net income and operating cash flow is primarily attributable to stock-based compensation, which has grown from $4.5M in 2024Q1 to $13.9M in 2026Q2. This suggests that reported losses overstate the actual cash burn, but the trend of widening OCF deficits indicates escalating operational cash requirements. Investors should monitor whether SBC growth reflects retention incentives or dilution concerns.

The FCF trajectory shows a modest improvement in 2026Q2 compared to the prior quarter, but the overall trend is one of sustained high burn, consistent with advancing clinical trials. The absence of revenue means FCF margins are undefined, and the company's cash position of $98.9M implies a runway of roughly five quarters at current burn rates. This suggests that without additional financing, the company may face a liquidity constraint within the next year.

The near-zero CapEx underscores that ELVN's value creation is driven by R&D and intellectual property rather than physical assets. This implies that the company's cash burn is almost entirely operational, with no significant capital intensity to constrain future scalability. However, as trials advance, potential investments in manufacturing or commercial infrastructure could alter this profile, warranting monitoring.

The variability in working capital adjustments likely reflects timing of clinical trial payments and vendor terms, rather than operational inefficiencies. The small magnitude relative to operating cash flow indicates that working capital is not a primary driver of cash burn. Investors should focus on the underlying R&D spend, which is the dominant cash outflow.

The absence of capital returns is typical for a pre-revenue biotech, but it underscores the company's reliance on external financing to fund operations. The lack of buybacks or dividends suggests management is prioritizing pipeline advancement over shareholder returns, which is rational given the early stage. However, the accelerating cash burn and modest cash balance imply that future financing events may be dilutive.

The cumulative gap between net income and operating cash flow is substantial, reflecting the growing use of stock-based compensation as a component of employee compensation. This suggests that while reported losses are large, the actual cash drain is lower, but the trend of increasing SBC may indicate dilution risk. Investors should adjust their runway calculations using operating cash flow rather than net income to avoid overestimating the company's financial staying power.